About this Research Topic
The field of nanomedicine, specifically the development and application of nanocarriers for diagnostic and therapeutic purposes, is a rapidly evolving area of research. These nanoscale carriers enhance the controlled delivery of therapeutic molecules by increasing endocytosis, improving tumor cellular uptake, and leveraging the enhanced permeability and retention effect (EPR). Concurrently, non-coding RNAs have emerged as key players in the malignant transformation process, influencing tumor aggressiveness, proliferation ability, metastatic potential, and immune evasion properties. However, the potential crosstalk between nanocarriers and non-coding RNAs in solid malignancies remains largely unexplored, necessitating further investigation.
The primary aim of this research topic is to elucidate the role of nanocarriers and non-coding RNAs in solid malignancies. This includes exploring the potential of nanocarriers as vehicles for non-coding RNAs, given their ability to improve the pharmacokinetic properties and half-lives of their payloads while minimizing off-target toxicity. Additionally, the research will investigate the role of liposomes, a well-known and reliable drug and gene delivery system frequently used in cancer treatment, in this context.
The scope of this research topic is twofold. Firstly, it aims to define the boundaries of the interaction between nanocarriers and non-coding RNAs in solid malignancies. Secondly, it invites articles addressing the following themes:
- The use of nanocarriers for non-coding RNAs, including miRNAs, lncRNAs, and circRNAs in cancer
- In-vitro and/or in-vivo studies investigating the role of nanocarriers in alleviating the immune suppressive microenvironment
- In-vitro and/or in-vivo studies investigating the role of nanocarriers in repressing cancer hallmarks
- In-vitro and/or in-vivo studies investigating the crosstalk between nanocarriers and non-coding RNAs
- The role of nanoparticles as detecting agents for non-coding RNAs acting as biomarkers for solid cancers.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation, are out of scope for this section and will not be accepted as part of this research topic.
The primary aim of this research topic is to elucidate the role of nanocarriers and non-coding RNAs in solid malignancies. This includes exploring the potential of nanocarriers as vehicles for non-coding RNAs, given their ability to improve the pharmacokinetic properties and half-lives of their payloads while minimizing off-target toxicity. Additionally, the research will investigate the role of liposomes, a well-known and reliable drug and gene delivery system frequently used in cancer treatment, in this context.
The scope of this research topic is twofold. Firstly, it aims to define the boundaries of the interaction between nanocarriers and non-coding RNAs in solid malignancies. Secondly, it invites articles addressing the following themes:
- The use of nanocarriers for non-coding RNAs, including miRNAs, lncRNAs, and circRNAs in cancer
- In-vitro and/or in-vivo studies investigating the role of nanocarriers in alleviating the immune suppressive microenvironment
- In-vitro and/or in-vivo studies investigating the role of nanocarriers in repressing cancer hallmarks
- In-vitro and/or in-vivo studies investigating the crosstalk between nanocarriers and non-coding RNAs
- The role of nanoparticles as detecting agents for non-coding RNAs acting as biomarkers for solid cancers.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation, are out of scope for this section and will not be accepted as part of this research topic.
Keywords: Nanoparticles, MicroRNAs, LncRNAs, CircRNAs, Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
